Medable Partners with Seqster to Integrate RWD into Decentralized Trials
Medable Inc. has announced a new partnership with Seqster to integrate real-time, real-world data streams into decentralized clinical trials in efforts to improve trial recruitment and participation.
“Patients want clinical trials to fit into their real-world experience, not the other way around,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “Working with Seqster, we can integrate data sources and data streams to provide clinicians with a more holistic view of patient health.”
Medable and Seqster are also partnering with Datavant to integrate and link de-identified data across the entire patient journey, including electronic health records, claims, and diagnostics, as well as emerging sources such as genomics, wearable devices, socioeconomic and behavioral data and more.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
